Navigation Links
Sinovac Adjourns Annual General Meeting
Date:9/4/2008

BEIJING, Sept. 4 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled for September 4, 2008 has been adjourned to September 18, 2008.

At the September 4, 2008 Annual General Meeting, the required quorum of a majority of the outstanding shares was not present. In accordance with Antigua law, the meeting is adjourned to September 18, 2008 (the same day two weeks after September 4), at 9 a.m. Beijing time at Sinovac's headquarters located at No. 39, Shangdi Xi Rd., Haidian District, Beijing, PRC (the same time and place as the originally scheduled meeting). Under Antigua law and in compliance with American Stock Exchange requirements, if a quorum is not present within thirty minutes of the appointed time for holding the adjourned meeting, the shareholders then present representing at least one-third of the total outstanding shares will constitute a quorum.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-9871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington/Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com

jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
2. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
3. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
4. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
5. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
6. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
7. Sinovac Biotech Holds Annual General Meeting
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
10. Sinovac Announces Adjournment of Annual General Meeting
11. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... ... Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner was named president ... Since then, he has served in a number of key leadership positions including secretary ... and exposition committees. In his professional career, Dr. Gardner is the director of product ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that Martine Rothblatt ... Therapeutics will provide an overview and update on the ... Annual Health Care Conference. The presentation will ... a.m. Eastern Time, and can be accessed via a ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a ... Board. Dr. Lamka will assist PathSensors in expanding the use of the company’s ... the CANARY® test platform for the detection of harmful pathogens, including a number ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group and ... Symposium as other research and development initiatives for potential stem cell protocol management for ... Stem Cells Group executives began meeting to establish a working agenda and foster initiatives ...
Breaking Biology Technology:
(Date:3/10/2016)... March 10, 2016   Unisys Corporation (NYSE: ... Protection (CBP) is testing its biometric identity solution at ... to help identify certain non-U.S. citizens leaving the ... test, designed to help determine the efficiency and accuracy of ... February and will run until May 2016. --> ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):